A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
about
The promise of neuroprotective agents in Parkinson's diseaseMitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug developmentCreatine for Parkinson's diseaseCreatine for Parkinson's diseaseThe role of oxidative stress in Parkinson's diseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesOxidative Stress in Neurodegenerative DiseasesLinked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatmentsA review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's diseaseAnti-Oxidants in Parkinson's Disease Therapy: A Critical Point of ViewPhosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effectsMitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifyingMultiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparatorPioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease.A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month resultsEffect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.Fall frequency and risk assessment in early Parkinson's diseaseCaffeine and progression of Parkinson diseaseExenatide and the treatment of patients with Parkinson's diseaseLongitudinal follow-up of SWEDD subjects in the PRECEPT StudyBayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trialInhibitors of cytochrome c release with therapeutic potential for Huntington's diseaseCritical data-based re-evaluation of minocycline as a putative specific microglia inhibitor.Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic interventionPotential future neuroprotective therapies for neurodegenerative disorders and stroke.Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Computationally simple estimation and improved efficiency for special cases of double truncation.The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trialsCombination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseasesTherapeutic use of creatine in brain or heart ischemia: available data and future perspectives.Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods.Creatine, L-carnitine, and ω3 polyunsaturated fatty acid supplementation from healthy to diseased skeletal muscle.Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
P2860
Q21129436-96E96C91-F39D-4D88-9708-BB241992650EQ22241837-1592103C-219F-4DAB-8443-73686BCAA9F1Q24193947-D96C86E4-F766-468E-B046-D840988522DFQ24203799-A0A52B8A-0685-4818-9A2C-4812D778135AQ24307946-7784A7A1-2A68-4AF6-9C4B-4AF976608576Q26747508-32C2AFC8-D907-45F9-83E8-FA4A18FA8295Q26801239-003838B3-ABE7-4D68-98E8-A39C291B1D69Q26995786-69DD802B-CB20-4C8D-A759-3CEA20468CACQ27311651-6E236410-CDEC-4726-A769-305821AB5604Q28084254-2832A602-2631-441B-8BEB-6C331B905490Q28482353-927EA7C9-6D19-4CFA-88CE-FCA2C9994A6EQ28732683-667B815A-047E-424E-B136-6239EC99CB5FQ28749656-2F6A5020-4241-4055-AB67-E855DC7FA5DFQ30357397-221A89C7-14EA-420E-A37B-6BA327971473Q30365907-111C2B7A-8914-4811-9BDA-CFA1C18B1DFFQ30407150-7401B9FF-956D-4464-BEF0-BF058D9DE6BCQ30407589-4752084D-5A04-4932-B0F5-2CBF7B6FA797Q30417007-9422E502-6E66-4981-8DD6-F9498668BE9CQ30418009-E5D062BC-BA01-41FF-A1AB-484AED01526AQ30432945-3A95CD2A-2F0E-4EE7-BA5A-FC5FA95581C6Q30540208-957AFE53-0B6E-4532-AA70-86276A7B5A6AQ30578973-28E10769-EAFB-4C61-B97C-AF7EA230216FQ30581777-670D8C76-2EFA-4265-8021-81E22B78EEBFQ30847955-7A6974EA-607D-4DE9-A2AC-1C3755DC36C6Q31104505-EBD5C7BA-086B-4A3C-844E-6819D4EAEBD0Q33663970-E08A2F3F-E8EB-4B31-94F0-C69346162A19Q33687436-902B038D-FB85-40AD-971A-ACBA4636E68EQ33731897-3071C9D9-36E1-427E-B1B8-1AF84CE0FB50Q33753874-B7859EC0-A953-4790-8D71-1A116A124CA9Q33758328-2C030B58-1202-45E4-A541-18E79EA2867DQ33760040-83F5B36A-5CC6-4013-BFAB-A97565C01ED9Q33837238-0AC82ED3-A038-4DBA-A465-39344F95F9EFQ33917550-7AF05025-15DF-4CA3-B41C-EAC6CC926B40Q34071942-144EDB5C-C310-4787-AF27-A7D10B9B3606Q34089086-BD8672A0-3EDD-4543-A5F2-8BA78EA38235Q34091447-80402D9D-5C6F-4DDF-835D-B1D7F8C248B3Q34174655-B75B0BEF-40C1-4124-8233-864F9128F831Q34177044-638B0BB3-1693-4804-8D97-72D9D2107B5BQ34272602-39434971-BF23-4C31-A322-B4142D9FC6F6Q34301396-685F2EAD-05C4-415F-AF5E-BD0952DC5442
P2860
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A randomized, double-blind, fu ...... ne in early Parkinson disease.
@en
A randomized, double-blind, fu ...... ne in early Parkinson disease.
@nl
type
label
A randomized, double-blind, fu ...... ne in early Parkinson disease.
@en
A randomized, double-blind, fu ...... ne in early Parkinson disease.
@nl
prefLabel
A randomized, double-blind, fu ...... ne in early Parkinson disease.
@en
A randomized, double-blind, fu ...... ne in early Parkinson disease.
@nl
P1433
P1476
A randomized, double-blind, fu ...... ne in early Parkinson disease.
@en
P2093
NINDS NET-PD Investigators
P304
P356
10.1212/01.WNL.0000201252.57661.E1
P407
P577
2006-02-15T00:00:00Z